Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stake Lifted by Barclays PLC

Barclays PLC boosted its position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 86.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,165 shares of the company’s stock after purchasing an additional 12,564 shares during the period. Barclays PLC’s holdings in Prelude Therapeutics were worth $57,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA grew its position in Prelude Therapeutics by 2.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 522,375 shares of the company’s stock worth $1,990,000 after buying an additional 14,226 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Prelude Therapeutics by 103.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after purchasing an additional 14,769 shares in the last quarter. Exchange Traded Concepts LLC raised its holdings in Prelude Therapeutics by 32.2% during the 3rd quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock worth $133,000 after buying an additional 15,682 shares during the period. XTX Topco Ltd acquired a new position in shares of Prelude Therapeutics in the third quarter worth about $100,000. Finally, Walleye Capital LLC raised its holdings in shares of Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after acquiring an additional 67,946 shares during the period. 79.72% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on PRLD shares. JMP Securities reissued a “market outperform” rating and set a $4.00 price target (down from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Prelude Therapeutics in a research note on Friday, November 8th.

Insider Transactions at Prelude Therapeutics

In other Prelude Therapeutics news, CEO Krishna Vaddi purchased 100,000 shares of the firm’s stock in a transaction on Wednesday, December 18th. The shares were purchased at an average price of $0.93 per share, for a total transaction of $93,000.00. Following the completion of the purchase, the chief executive officer now directly owns 1,167,275 shares of the company’s stock, valued at approximately $1,085,565.75. This represents a 9.37 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrew Combs acquired 60,000 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was acquired at an average price of $1.37 per share, with a total value of $82,200.00. Following the purchase, the insider now owns 377,623 shares in the company, valued at approximately $517,343.51. This represents a 18.89 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 198,075 shares of company stock worth $213,486. Insiders own 62.80% of the company’s stock.

Prelude Therapeutics Stock Performance

Shares of NASDAQ PRLD opened at $1.14 on Friday. Prelude Therapeutics Incorporated has a 52 week low of $0.80 and a 52 week high of $6.80. The business’s 50-day simple moving average is $1.10 and its 200-day simple moving average is $2.92. The firm has a market cap of $62.74 million, a price-to-earnings ratio of -0.64 and a beta of 1.39.

Prelude Therapeutics (NASDAQ:PRLD) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.05. The firm had revenue of $3.00 million for the quarter. As a group, equities research analysts forecast that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current year.

Prelude Therapeutics Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.